A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

The randomised trial saw over half of patients dosed with Sunosi were able to achieve clinical response to the therapy ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Sunosi is a prescription drug that’s prescribed for excessive daytime sleepiness (EDS) in certain adults. It is a controlled substance. Sunosi is a part of the class of drugs called dopamine ...

Axsome currently markets solriamfetol as Sunosi for treating narcolepsy. Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S ...

Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, ...